Channel Therapeutics Corporation (AMEX:CHRO) does about 350.72K shares in volume on a normal day but saw 32243495 shares change hands in the recent trading day. The company now has a market cap of 16.04M USD. Its current market price is $2.66, marking an increase of 40.00% compared to the previous close of $1.90. The 52 week high reached by this stock is $6.00 whilst the lowest price level in 52 weeks is $0.45.
Channel Therapeutics Corporation (CHRO) has a 20-day trading average at $0.9300 and the current price is -55.67% off the 52-week high compared with 491.11% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.7600 and its 200-day simple moving average is $1.0800. If we look at the stock’s price movements over the week, volatility stands at 70.69%, which decreases to 28.74% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 91.30 to suggest the stock is overbought.
The consensus objective for the share price is $8.50, suggesting that the stock has a potential upside of 68.71% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The current price level is 186.00%, 252.17%, and 146.12% away from its SMA20, SMA50, and SMA200 respectively, with the CHRO price moving below the 50-day SMA on current market day. Channel Therapeutics Corporation (CHRO) stock is up 195.56% over the week and 329.38% over the past month. Its price is 314.98% year-to-date.
The company’s next earnings report forecasts estimating quarterly EPS at -0.21 and -1.3 for whole year.
To reach the target analysts have set, the stock logically needs to grow 68.71 percent from here.
Outstanding shares total 5.82M with insiders holding 80.76% of the shares and institutional holders owning 7.07% of the company’s common stock.
